Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® ...

The UnitedHealth Group division is taking Johnson & Johnson's Stelara — one of the most popular, best-known and most expensive "biologic" anti-inflammatory drugs — off the standard formulary for many ...

BMY depends on label expansion of approved drugs and approval of new drugs to stabilize its revenue base as its legacy drugs ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced enrolling the ...

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.15%, is indicated ...

AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is ...

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

On Monday, Morgan Stanley resumed its coverage of Alumis Inc. (NASDAQ: ALMS) with an Overweight rating and a $23 price target ...

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...

Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health ...

Bristol MyersBMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis ...